提醒

Compass Therapeutics Inc. (CMPX)

NasdaqCM: CMPX · 即時價格 · USD

2.19

-0.01 (-0.45%)

收盤時： Aug 12, 2026, 12:11 PM

-0.45% (1D)

買價	1.59
市值	393.49M
營收 (ttm)	n/a
淨利（ttm）	-73.45M
貝塔	0.82
EPS (ttm)	-0.39
本益比（ttm）	n/a
正向 PE	-4.18
P/B (ttm)	2.37
P/S (ttm)	n/a
Earnings Date	Nov 5, 2026

賣價	2.8
成交量	1,375,842
20 日平均成交量	3,611,332
打開	2.20
上一頁關閉	2.20
日間範圍	2.18 - 2.24
52 週範圍	1.61 - 6.88
分析師	Strong Buy
目標價	7 (219.63%)
股利	n/a
Ex-股利日期	n/a

關於CMPX

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an Ig...

[閱讀更多]

工業 Biotechnology

部門 Healthcare

IPO 日期 Apr 5, 2021

員工 39

證券交易所 NasdaqCM

股票代號 CMPX

網站 https://www.compasstherapeutics.com

完整的公司簡介

財務表現

Compass Therapeutics 在 2025 年的營收為 0，較前一年的 850K 減少 -100%。淨利為 -66.49M，較前期增加 34.66%。

財務報表

分析師預測

根據12 分析師評等，CMPX股票的平均評等為「Strong Buy」。 12個月股價預測為7，與最新價格相比為上漲空間的219.63%。

股票預測

獲利驚喜

Compass Therapeutics 已於 Aug 6, 2026 公布季度財報：

營收的 $0 錯過估計 $0, 與 NaN% YoY 成長.

EPS 的 -0.13 錯過估計 -0.02, 與 7.14% YoY 成長.

下次財報發布

Compass Therapeutics Inc. 定於發布財報 Nov 5, 2026, 開市前。
分析師預估營收 ... 升級

新聞動態

1 月前 · Insider Monkey

Here’s Why Citizens Maintains a Buy on Compass Therapeutics (CMPX)

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the Best Small-Cap Growth Stocks to Invest In Now. Recently, on June 4, Citizens reiterated a Market Outperform rating on the stock with a price tar...

1 月前 · Insider Monkey

How Compass Therapeutics (CMPX) Is Moving Tovecimig Toward a Potential Biliary Tract Cancer Filing

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main story is tovecimig, an experimental cancer treatment being developed for...

2 月前 · MarketBeat

Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win

Compass Therapeutics (NASDAQ:CMPX) Chief Executive Officer Tom Schuetz said the company is preparing for a key U.S. Food and Drug Administration meeting on tovecimig, its DLL4/VEGF bispecific antibody...

2 月前 · Insider Monkey

Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M

Compass Therapeutics Inc. (NASDAQ:CMPX) is one of the best NASDAQ stocks under $5 to buy right now. On May 5, Compass Therapeutics reported a Q1 2026 net loss of $18.3 million, or $0.10 per share. R&D...

3 月前 · Insider Monkey

Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX)

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the 10 Best Day Trading Penny Stocks to Buy. On April 28, 2026, Canaccord lowered its price target on Compass Therapeutics, Inc. (NASDAQ:CMPX) to $7 ...

第 1 頁，共 2 頁

Compass Therapeutics Inc. (CMPX)